XML 23 R2.htm IDEA: XBRL DOCUMENT v3.23.2Close
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total revenue $ 2,456.0 $ 2,589.1 $ 4,919.0 $ 5,120.9 Close
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 592.7 484.0 1,255.5 1,237.9
Research and development 584.2 528.6 1,154.8 1,080.3
Selling, general and administrative 548.0 572.6 1,153.0 1,207.5
Amortization and impairment of acquired intangible assets 52.9 67.5 103.1 134.4
Collaboration profit sharing/(loss reimbursement) 56.9 29.4 114.0 (87.9)
(Gain) loss on fair value remeasurement of contingent consideration 0.0 (4.5) 0.0 (11.6)
Restructuring charges 34.4 70.6 44.0 108.7
Other (income) expense, net (121.2) (428.6) (51.8) (165.3)
Total cost and expense 1,747.9 1,319.6 3,772.6 3,504.0 Close
Income before income tax expense and equity in loss of investee, net of tax 708.1 1,269.5 1,146.4 1,616.9 Close
Income tax (benefit) expense 114.8 216.7 165.5 342.3 Close
Equity in (income) loss of investee, net of tax 0.0 (5.9) 0.0 (2.6)
Net income 593.3 1,058.7 980.9 1,277.2 Close
Net income (loss) attributable to noncontrolling interests, net of tax 1.7 0.7 1.4 (84.6)
Net income attributable to Biogen Inc. $ 591.6 $ 1,058.0 $ 979.5 $ 1,361.8
Net income per share:        
Basic earnings per share attributable to Biogen Inc. $ 4.09 $ 7.25 $ 6.78 $ 9.30
Diluted earnings per share attributable to Biogen Inc. $ 4.07 $ 7.24 $ 6.74 $ 9.27
Weighted-average shares used in calculating:        
Basic earnings per share attributable to Biogen Inc. 144,700 145,900 144,600 146,500
Diluted earnings per share attributable to Biogen Inc. 145,500 146,200 145,400 146,800
Product, net        
Total revenue $ 1,845.8 $ 2,054.9 $ 3,609.1 $ 4,121.2
LEQEMBI Collaboration        
Total revenue (20.7) 0.0 (39.6) 0.0
Revenue from anti-CD20 therapeutic programs        
Total revenue 433.4 436.3 832.9 835.7
Contract manufacturing, royalty and other revenue        
Total revenue $ 197.5 $ 97.9 $ 516.6 $ 164.0